Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

The report, from 340B Health, claims that changes proposed by major drugmakers to replace upfront discounts with post-sale rebates for outpatient drugs would hit safety-net hospitals with significant ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Key Points Prime Medicine posted GAAP revenue of $1.1 million, missing analyst expectations by over 70% (GAAP). Reported net loss (GAAP) narrowed to $52.6 million, driven by reduced research and ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

Bristol-Myers Squibb recently saw a 6.39% drop in its stock value, with weak momentum and bearish signals from technical ...

In 2017, Megan Wanzo was pursuing health care ethics, uncertain but hopeful that she was on the right path, when she attended ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...